Abstract

Epithelioid hemangioendothelioma is an ultra-rare cancer driven by YAP–CAMTA1 fusion. Based on the link of the fusion to the MEK pathway, SARC33 was performed. It is a phase 2 trial examining trametinib that missed its primary objective by RECIST but demonstrated patient-reported outcome benefits in improved pain.

Original languageEnglish
Pages (from-to)4552-4553
Number of pages2
JournalClinical Cancer Research
Volume30
Issue number20
DOIs
StatePublished - Oct 15 2024

Fingerprint

Dive into the research topics of 'Is It Time to Resist Using RECIST as a Primary Endpoint for Rare Tumor Trials?'. Together they form a unique fingerprint.

Cite this